Cantor


Cantor Now Sees Bigger Market Opportunity for Array Biopharma Inc’s (ARRY) Binimetinib/Encorafenib Following ESMO Presentation

Forecasting a potential $500 million yearly sales opportunity ahead, the analyst lifts price target on Array.

Cantor Believes Teva Pharmaceutical Industries Ltr (ADR) New CEO Will Unlock Value for Shares

Analyst Louise Chen cheers that new Danish CEO means “good news” for Tesla investors.

Mallinckrodt PLC (MNK) Inomax Sales to Reach $505.9 Million by 2017 Despite Losing Patent Battle: Cantor

Solid MNK business model will eventually attract investors, says analyst.

Cantor Offers Bullish Forecast on Synergy Pharmaceuticals Inc (SGYP) Following 2Q Earnings Showcase

Investors to get a better viewpoint of Trulance during today’s call, says analyst.

Amazon.com, Inc. (AMZN) to Capture Significant U.S. Grocery Market Share by 2022: Cantor

Whole Foods Acquisition to to Bring $17B of Annualized Revenue to Amazon’s Table, Says Kip Paulson

Amarin Corporation plc (ADR) (AMRN) Has New Advantage In Defending Market Share After Filing ITC Lawsuit

Amarin Ventures to Shield Omega-3 Candidate Vascepa from Adverse Competition

Novartis’ Data Offers Insights into Amarin Corporation plc’s (ADR) (AMRN) REDUCE-IT Trial

Novartis’ Results Could Be a Good Looking Glass into Successful Commercial Future for Amarin

Omeros Corporation (OMER) Gets Price Target Boost on Omidria Q2 Sales Beat

Analyst Cautiously Celebrating Biotech Player’s Stellar Q2 Performance from the Sidelines

Cantor Bets on Opko Health Inc. (OPK); Sees 240% Upside

Looking for a reason to buy shares of Opko Health Inc. (NASDAQ:OPK)?

Cantor Shines Light on TherapeuticsMD Inc (TXMD) Following Publication of Clinical Data in Menopause

Cantor analyst William Tanner is out today with a few insights on TherapeuticsMD Inc (NYSEMKT:TXMD), after the drug maker announced the publication of a manuscript …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts